Clinical Trials Browser

Phase 1 × ficlatuzumab × Other hematologic neoplasm × Clear all

NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute